Welcome to our dedicated page for Health Catalyst news (Ticker: HCAT), a resource for investors and traders seeking the latest updates and insights on Health Catalyst stock.
Health Catalyst, Inc. reports developments tied to healthcare intelligence, data and analytics technology, and professional services for healthcare organizations. Company updates commonly cover operating results, revenue and Adjusted EBITDA guidance, and the use of AI-driven technology and domain expertise to support health systems across cost, clinical, and consumer performance.
Recurring news also includes leadership and board governance changes, shareholder-related board appointments, investor conference participation, and updates on strategic focus areas for its healthcare data platform, analytics applications, implementation, advisory, outsourcing, and improvement services.
Med-Metrix, backed by Harvest Partners and A&M Capital Partners, entered a definitive agreement to acquire Vitalware from Health Catalyst (NASDAQ: HCAT).
The deal aims to strengthen Med-Metrix's mid-revenue cycle platform, enhancing charge capture, coding accuracy, revenue integrity, and compliance for health system clients, subject to customary closing conditions.
Health Catalyst (Nasdaq: HCAT) signed a definitive agreement to divest its mid-revenue cycle business, Vitalware, to Med-Metrix for $147 million in cash. The company expects this move to sharpen its focus on core technology and AI-driven healthcare improvement.
Net proceeds plus cash on hand are planned to fully repay and terminate a ~$160 million senior secured term loan, which Health Catalyst expects will strengthen its balance sheet and increase financial flexibility. Vitalware generated approximately $37 million in fiscal 2025 revenue. Closing is expected in 2026, subject to specified conditions and regulatory waiting periods.
Health Catalyst (Nasdaq: HCAT) reported first quarter 2026 results. GAAP total revenue was $70.8 million, down 11% year over year, with gross margin of 39%. GAAP net loss widened to $111.0 million.
Non-GAAP Adjusted EBITDA was $9.1 million, up 46%, and Adjusted gross margin reached 51%. 2026 guidance calls for total revenue of $260–$265 million and Adjusted EBITDA of $30–$33 million. Q2 2026 revenue is guided to $68–$70 million.
Health Catalyst (Nasdaq: HCAT) will release first quarter 2026 operating results on Monday, May 11, 2026 after market close and will host a conference call at 5:00 pm ET the same day.
Dial-in numbers, conference ID HCATQ126, a live audio webcast and an on‑demand replay (available ~90 days) are provided on the company investor site.
Health Catalyst (Nasdaq: HCAT) appointed Steve Nelson, Executive Vice President and President of Aetna, to its Board of Directors effective May 1, 2026. Nelson brings payer and provider leadership, including prior CEO roles at ChenMed and UnitedHealthcare, joining after recent CEO and chairman appointments to support the company's coordinated strategy on cost, clinical outcomes, and consumer experience.
Health Catalyst (Nasdaq: HCAT) reported 2025 results: total revenue $311.1M (up 1% YoY) and Adjusted EBITDA $41.4M (up 59% YoY). GAAP net loss widened to $178.0M. Platform Clients grew to 162 and dollar-based retention fell to 93%. Q1 2026 guidance: revenue $68–70M, Adjusted EBITDA $7–8M.
Management cited opportunities and areas to improve and is conducting an internal strategic and operational review amid a CEO transition.
Health Catalyst (Nasdaq: HCAT) will release its fourth quarter and year-end 2025 operating results on Thursday, March 12, 2026, after market close, and will host a conference call the same day at 5:00 pm ET. The call includes dial-in numbers, conference ID “HCATQ425,” and a live audio webcast at the company investor site.
A webcast replay will be available on-demand at the same link shortly after the call and will remain available for approximately 90 days.
Health Catalyst (NASDAQ: HCAT) appointed Ben Albert as Chief Executive Officer, effective February 12, 2026, accelerating its previously announced succession plan. Dan Burton stepped down as CEO and will serve as a strategic advisor under a planned transition agreement. The Board will be reduced to five directors prior to the 2026 Annual Meeting.
Mr. Albert, promoted from President and COO after joining that role in September 2025, previously streamlined leadership to focus resources on cost, operational efficiency, clinical quality, and consumer experience.
Health Catalyst (Nasdaq: HCAT) announced that Matt Arens, CEO and founder of First Light Asset Management and representative of the company's largest shareholder, joined the board effective Dec. 1, 2025. First Light and Arens collectively own approximately 13.9 million shares, or about 19% of outstanding common stock. The company said Arens brings capital-markets experience focused on micro- to mid-cap healthcare investing and that his perspective will support strategic focus and shareholder value efforts.
The release also said director Matthew Kolb will not stand for re-election at the 2026 annual meeting and will continue to serve until that meeting.
Health Catalyst (Nasdaq: HCAT) said senior management will participate in multiple investor conferences in Nov–Dec 2025. Key events and appearances include:
- Nov 19, 2025, 3:00pm CT – Fireside chat at The Stephens Annual Investment Conference in Nashville with Ben Albert, Jason Alger, and Matt Hopper.
- Nov 20, 2025 – 1x1 meeting opportunities at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York with Dan Burton, Ben Albert, Jason Alger, and Matt Hopper.
- Dec 2, 2025, 8:20am ET – Fireside chat at the 8th Annual Evercore Healthcare Conference in Miami with Dan Burton, Ben Albert, Jason Alger, and Matt Hopper.
- Dec 3, 2025 – 1x1 meeting opportunities at Citi’s 2025 Global Healthcare Conference in Miami with Dan Burton, Ben Albert, Jason Alger, and Matt Hopper.
The announcements list dates, times, locations, and participating executives for investor engagement in late 2025.